PD-L1 ADC
Global PD-L1 ADC Race Heats Up as Pfizer’s PF-08046054 Becomes First in Phase III
Pfizer’s PF-08046054 is the first PD-L1 ADC in Phase III. The competitive landscape includes China’s Henlius, highlighting growing global innovation in ADC therapies.